510(k) Sponsors Should Be Wary Of Informal Talk With FDA, Attorney Says
This article was originally published in The Gray Sheet
Informal communications via telephone or e-mail before or during a 510(k) submission can be an efficient approach for sponsors, but companies should be aware of the pitfalls, says Hogan & Hartson Partner and FDA device specialist John Smith
You may also be interested in...
In a sign of the intense scrutiny CDRH is facing under the new administration, FDA is taking the rare step of performing an internal review of its decision process for a recently 510(k)-cleared device. The inquiry could potentially lead to a "reconsideration" of the clearance, the agency says
In search of the latest insider tips on navigating FDA's pre-market review process, "The Gray Sheet" invited three experts to speak on the topic. They answered our questions during a panel discussion Oct. 24 at Windhover Information's 1In3 East meeting in Boston
A Dec. 28 final FDA guidance document lays out a path for more informal interaction between agency reviewers and device companies while preserving CDRH's options to place holds on premarket reviews